Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 931.

https://doi.org/10.1182/blood-2024-202017

Published: 2024

Journal Articles

Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients

Louis Williams, Danai Dima, Hanny Sawaf, Ali Mehdi, Daniel Cancilla, Hira Shaikh, Faiz Anwer, Sandra Mazzoni, Beth M. Faiman, Jack Khouri, Christy J. Samaras, Jason Valent, Shahzad Raza

Blood (2024) 144 (Supplement 1): 1918.

https://doi.org/10.1182/blood-2024-210799

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Blood (2024) 144 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2024-206357

Published: 2024

Journal Articles

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 897.

https://doi.org/10.1182/blood-2024-203409

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 934.

https://doi.org/10.1182/blood-2024-205989

Published: 2024

Journal Articles

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Utkarsh Goel, Danai Dima, James A Davis, Aliya Rashid, William Wesson, Shaun DeJarnette, Fauzia Ullah, Evguenia Ouchveridze, Mariam Markouli, Claire Yun Kyoung Ryu Tiger, Louis Williams, Sandra Mazzoni, Beth M. Faiman, Craig Sauter, Faiz Anwer, Shahzad Raza, Leyla O. Shune, Jack Khouri

Blood (2024) 144 (Supplement 1): 4708.

https://doi.org/10.1182/blood-2024-203984

Published: 2024

Journal Articles

US Physicians' Perspective and Practice Patterns for the Management of Transplant-Eligible-Newly Diagnosed Multiple Myeloma

Yara Shatnawi, Zainab Motiwala, Faiz Anwer, Danai Dima, Louis S Williams, Nausheen Ahmed, Sandra Mazzoni, Jack Khouri, Joslyn Rudoni, Mikhaila Rice, Diana Basali, Christy J. Samaras, Jason Valent, Al-Ola Abdallah, Tara Roy, Beth M. Faiman, Shahzad Raza

Blood (2024) 144 (Supplement 1): 7044.

https://doi.org/10.1182/blood-2024-212202

Published: 2024

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis

Carmelo Gurnari, Hussein Awada, Simona Pagliuca, Danai Dima, Fauzia Ullah, Naomi Kawashima, Yasuo Kubota, Ceylan Colak, Valeria Visconte, Bhumika J. Patel, Vikram Dhillon, Naimisha Marneni, Suresh Kumar Balasubramanian, Ashwin Kishtagari, Taha Bat, Jaroslaw P. Maciejewski

Blood (2024) 144 (2): 145–155.

https://doi.org/10.1182/blood.2024023988

Published: 2024

Journal Articles

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

David Kaplan, Eric Christian, Jason Valent, Faiz Anwer, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Louis S. Williams, Danai Dima, Kelly Shepherd, Jared Fennema, Sherry Fada, Megan Nakashima, Mazen Hanna, Hillard M. Lazarus, Jack Khouri

Blood (2023) 142 (Supplement 1): 5031.

https://doi.org/10.1182/blood-2023-180735

Published: 2023

Journal Articles

Insights into Large Granular Lymphocytic Leukemia-Associated Hemolytic Anemia: Clinical Associations, Therapeutic Responses, and Optimal Management Strategies from a Large Institutional Study

Olisaemeka Ogbue, Serhan Unlu, Danai Dima, Carlos Bravo-Perez, Nakisha D Williams, Arooj Ahmed, Sindhusha Veeraballi, Arda Durmaz, Fauzia Ullah, Carmelo Gurnari, Valeria Visconte, Jaroslaw P. Maciejewski

Blood (2023) 142 (Supplement 1): 5167.

https://doi.org/10.1182/blood-2023-186071

Published: 2023

Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2023-187565

Published: 2023

Journal Articles

Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

James A Davis, Danai Dima, Nausheen Ahmed, Shaun DeJarnette, Joseph P McGuirk, Jack Khouri, Jason Valent, Faiz Anwer, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2023-179981

Published: 2023

Journal Articles

Del(20q) As a Somatic Gene Rescue in Adult Patients: Can Germline Mutations Other Than SBDS be Found in Affected Patients?

Mark Orland, Yasuo Kubota, Danai Dima, Carlos Bravo-Perez, Luca Guarnera, Carmelo Gurnari, Jaroslaw P. Maciejewski, Valeria Visconte

Blood (2023) 142 (Supplement 1): 4095.

https://doi.org/10.1182/blood-2023-191101

Published: 2023

Journal Articles

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Mark Orland, Danai Dima, Fauzia Ullah, Hussein Awada, Diana Basali, Beth M. Faiman, Cynthia Scott, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Shahzad Raza, Jack Khouri

Blood (2023) 142 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2023-183030

Published: 2023

Journal Articles

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Rawan Atallah, Md Saiful Islam Saif, Danai Dima, Anuj Shrestha, Faiz Anwer, Muhammad Umair Mushtaq, Forat Lutfi, Leyla Shune, Hamza Hashmi, Siddhartha Ganguly, Joseph P McGuirk, Shebli Atrash, Al-Ola Abdallah, Rahul Banerjee, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6678.

https://doi.org/10.1182/blood-2023-181218

Published: 2023

Journal Articles

Pooled Analysis on Bispecific Antibody-Related Toxicities in Multiple Myeloma

Mobina Golmohammadi, Danai Dima, Maram Albayyadhi, Azam Moradi, Shahzad Raza, Majid Jaberi-Douraki

Blood (2023) 142 (Supplement 1): 1953.

https://doi.org/10.1182/blood-2023-191305

Published: 2023

NARROW

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

US Physicians' Perspective and Practice Patterns for the Management of Transplant-Eligible-Newly Diagnosed Multiple Myeloma

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

Insights into Large Granular Lymphocytic Leukemia-Associated Hemolytic Anemia: Clinical Associations, Therapeutic Responses, and Optimal Management Strategies from a Large Institutional Study

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Del(20q) As a Somatic Gene Rescue in Adult Patients: Can Germline Mutations Other Than SBDS be Found in Affected Patients?

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Pooled Analysis on Bispecific Antibody-Related Toxicities in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only